Novo Nordisk vs. Pfizer: Healthcare Stock Comparison for 2026

As the global healthcare sector pivots toward weight-loss therapeutics and chronic care portfolios, market participants are evaluating the valuation and structural fundamentals of Novo Nordisk A/S and Pfizer Inc. amid recent equity performance.

### Session Tape - Novo Nordisk A/S: $37.23 (-0.47% / -$0.18) - Pfizer Inc.: $27.60 (-1.87% / -$0.53)

## Catalyst Analysis: Fundamental Metrics and Valuation Spans Financial comparisons underscore structural differences in margin profiles and cash generation. Novo Nordisk registers a market capitalization of $125 billion with a 52-week range spanning $35.12 to $64.16, alongside an 80.65% gross margin, a P/E ratio of 9.13, trailing twelve-month EPS of $4.09, and a dividend yield of $1.80 (4.80%).

Conversely, Pfizer carries a $160 billion market capitalization with a 52-week range between $23.62 and $29.21, a gross margin of 64.83%, a P/E ratio of 37.24, trailing twelve-month EPS of $0.76, and a dividend yield of $1.72 (6.12%). Portfolio concentration metrics indicate diverse revenue dependencies across individual product lines within the broader pharmaceutical industry.

### Money Play - Market participants reviewing large-cap healthcare options should assess the fundamental divergence between Novo Nordisk's lower multiple with higher gross margins and Pfizer's higher dividend yield alongside elevated valuation multiples.